Claudin 18.2 (CLDN18.2) expression prevalence, prognostication and clinical variables in gastric and gastroesophageal junction adenocarcinoma patient samples

被引：0
|
作者：
Sewastjanow, Matheus
Yamashita, Kohei
Iwata, Kenneth K.
Moran, Diarmuid
Elsouda, Dina
Pizzi, Melissa
Vicentini, Ernesto Rosa
Shanbhag, Namita
Ta, Anh
Waters, Rebecca
Chatterjee, Deyali
Ajani, Jaffer
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2141
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2141
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Clinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer
    Baek, Jin Ho
    Park, Dong Jin
    Kim, Gyu Yeol
    Cheon, Jaekyung
    Kang, Byung Woog
    Cha, Hee Jeong
    Kim, Jong Gwang
    ANTICANCER RESEARCH, 2019, 39 (12) : 6973 - 6979
  • [32] High Prevalence of Claudin 18.2 Expression in Japanese Patients with Gastric Cancer.
    Tureci, Ozlem
    Itoh, Kyogo
    Yamaguchi, Rin
    Mukhina, Svetlana
    Sahin, Ugur
    Rohde, Christoph
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] First-line (1L) zolbetuximab plus chemotherapy in patients (pts) with claudin 18.2 (CLDN18.2) +, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: A pooled final analysis of SPOTLIGHT plus GLOW
    Kang, Y-K.
    Shah, M. A.
    Shitara, K.
    Ajani, J. A.
    Lordick, F.
    Van Cutsem, E.
    Ilson, D. H.
    Klempner, S. J.
    Yamaguchi, K.
    Nakajima, T.
    Cao, Y. J.
    Li, R.
    Moran, D.
    Pophale, R. R.
    Ranganath, R.
    Xu, R-H.
    ANNALS OF ONCOLOGY, 2024, 35 : S895 - S895
  • [34] CLDN18.2 expression in resectable gastroesophageal cancers: associated clinical and molecular signatures and impact of neoadjuvant chemotherapy on intra-tumour heterogeneity
    Cammarota, Antonella
    Devonshire, Ginny
    Miremadi, Ahmad
    Zhuang, Lizhe
    Zamani, Shawn
    Smith, Rebecca
    Masque-Soler, Neus
    Ustaoglu, Ahsen
    Rimassa, Lorenza
    Fitzgerald, Rebecca
    Smyth, Elizabeth
    BRITISH JOURNAL OF SURGERY, 2023, 110
  • [35] The impact of CLDN18.2 expression on effector cells mediating antibody-dependent cellular cytotoxicity in gastric cancer
    Matsuishi, Akira
    Nakajima, Shotaro
    Saito, Motonobu
    Saito, Katsuharu
    Fukai, Satoshi
    Tsumuraya, Hideaki
    Kanoda, Ryo
    Kikuchi, Tomohiro
    Nirei, Azuma
    Kaneta, Akinao
    Okayama, Hirokazu
    Mimura, Kosaku
    Hanayama, Hiroyuki
    Sakamoto, Wataru
    Momma, Tomoyuki
    Saze, Zenichiro
    Kono, Koji
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [36] ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
    Klempner, Samuel J.
    Lee, Keun-Wook
    Shitara, Kohei
    Metges, Jean-Phillippe
    Lonardi, Sara
    Ilson, David H.
    Fazio, Nicola
    Kim, Tae Yong
    Bai, Li-Yuan
    Moran, Diarmuid
    Yang, Jianning
    Arozullah, Ahsan
    Park, Jung Wook
    Raizer, Jeffrey J.
    Bang, Yung-Jue
    Shah, Manish A.
    CLINICAL CANCER RESEARCH, 2023, 29 (19) : 3882 - 3891
  • [37] Expression of Claudin 18.2 and HER2 in gastric, gastroesophageal junction, and esophageal cancers: Results from the FAST study.
    Schuler, Martin H.
    Al-Batran, Salah-Eddin
    Zvirbule, Zanete
    Manikhas, Georgy
    Lordick, Florian
    Rusyn, Andriy V.
    Vynnychenko, Ihor
    Dudov, Assen
    Bazin, Igor
    Melichar, Bohuslav
    Dhaene, Karl
    Wiechen, Kai
    Maurus, Daniel
    Tureci, Ozlem
    Sahin, Ugur
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [38] Zolbetuximab + CAPOX in 1L Claudin-18.2+(CLDN18.2+)/HER2-Locally Advanced (LA) Unresectable or Metastatic Gastric or Gastroesophageal Junction (mG/GEJ) Adenocarcinoma: Primary Phase 3 Results From GLOW
    Lordick, F.
    Xu, R. -H
    Shitara, K.
    Ajani, J. A.
    Bang, Y. -J
    Enzinger, P.
    Ilson, D.
    Van Cutsem, E.
    Gallego Plazas, J.
    Huang, J.
    Shen, L.
    Oh, S. C.
    Sunpaweravong, P.
    Hoo, Soo H. F.
    Turk, H. M.
    Park, J. W.
    Moran, D.
    Bhattacharya, P.
    Arozullah, A.
    Shah, M. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 116 - 117
  • [39] Zolbetuximab + CAPOX in 1L claudin-18.2+(CLDN18.2+)/HER22locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW.
    Xu, Rui-hua
    Shitara, Kohei
    Ajani, Jaffer A.
    Bang, Yung-Jue
    Enzinger, Peter C.
    Ilson, David H.
    Lordick, Florian
    Van Cutsem, Eric
    Plazas, Javier Gallego
    Huang, Jing
    Shen, Lin
    Oh, Sang Cheul
    Sunpaweravong, Patrapim
    Hoo, Hwoei Fen Soo
    Turk, Haci M.
    Park, Jung Wook
    Moran, Diarmuid Martin
    Bhattacharya, Pranob P.
    Arozullah, Ahsan
    Shah, Manish A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [40] Zolbetuximab + CAPOX in 1L claudin-18.2+(CLDN18.2+)/HER2-locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW.
    Xu, Rui-Hua
    Shitara, Kohei
    Ajani, Jaffer A.
    Bang, Yung-Jue
    Enzinger, Peter C.
    Ilson, David H.
    Lordick, Florian
    Van Cutsem, Eric
    Gallego Plazas, Javier
    Huang, Jing
    Shen, Lin
    Oh, Sang Cheul
    Sunpaweravong, Patrapim
    Soo Hoo, Hwoei Fen
    Turk, Haci M.
    Park, Jung Wook
    Moran, Diarmuid Martin
    Bhattacharya, Pranob P.
    Arozullah, Ahsan
    Shah, Manish A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (36_SUPPL) : 405736 - 405736
12345